USPTO serial 97052171
NEOFORDEX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 1, 2022
- Examiner
- ENGEL, MICHAEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NEOFORDEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Boulogne-Billancourt, FR
Boulogne-Billancourt, FR
Boulogne-Billancourt, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Pina Campagna
Pina Campagna CARTER, DELUCA & FARRELL LLP576 BROAD HOLLOW RD.MELVILLE, NY 11747UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, namely, amyloses, and purpura, namely, thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, namely, colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, namely, primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, namely, lymphomas, namely, Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, namely, multiple myeloma, and leukemia. chemical preparations for medical and pharmaceutical use for treating haematological diseases, namely, amyloses, and purpura, especially thrombocytopenic purpura | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 1, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 1, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 16, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 16, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 27, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 14, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 13, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 12, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 12, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 5, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 5, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 5, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 29, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 27, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 2, 2021 | NWAP | NEW APPLICATION ENTERED | — |